世界千強藥企,石藥(1093.HK)上升至第25位
近日,Torreya公司公佈了《世界千強藥企報吿》。該報吿按估值對於全球前1000家藥企進行了排名,提供了2021年全球製藥行業的最新發展概況。石藥集團(1093.HK)再次進入該榜單,位列第25名,在中國本土入榜藥企中排名第二位。
報吿顯示,石藥集團以65億美元的年收入和470億美元估值,位列第25名,較2020年的30位,進一步上升5個名次,在中國本土入榜藥企中排名第二位。
在該報吿針對各大治療領域的排名中,石藥集團在中樞神經藥品領域繼續發揮傳統優勢,躍居全球藥企第一位,充分體現了在該領域內的領軍地位。報吿中稱,石藥集團是中國最大的中樞神經藥品經銷商,近些年來取得了優異的銷售業績。
排名的變化印證的是石藥集團業績增長的穩定性,近十年來,石藥集團以創新為戰略,以研發為驅動,以產業化為基礎,以國際化為方向,實現了收入、利潤平均雙位數的增長,成為國內藥企轉型升級,創新發展的典範。
據報吿內容,在本次1000強藥企中,中國獨佔249家。全球Top100藥企中,中國強勢入圍19家,這充分説明中國製藥企業風頭正勁,在全球產業競爭中優勢日漸凸顯,體現了全球製藥產業價值正向中國等亞洲地區轉移的大趨勢。
Torreya是一家全球性的投資銀行,在六大洲均設有分支機構,為生命科學行業相關的公司提供技術支持,在併購、醫藥資產出售、資本市場和許可交易方面提供諮詢服務。自2007年成立以來,該公司為客户提供的交易額超過1000億美元,主要涉及生物技術、品牌製藥、仿製藥和生命科學領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.